Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
VYNE Therapeutics Inc (NASDAQ: VYNE) closed the day trading at $0.4 down -72.35% from the previous closing price of $1.44. In other words, the price has decreased by -$72.35 from its previous closing price. On the day, 37.69 million shares were traded. VYNE stock price reached its highest trading level at $0.4427 during the session, while it also had its lowest trading level at $0.36.
Ratios:
For a better understanding of VYNE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.47 and its Current Ratio is at 4.47. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on November 18, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 6634296 and an Enterprise Value of -43574708. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.06 while its Price-to-Book (P/B) ratio in mrq is 0.14. Its current Enterprise Value per Revenue stands at -72.024.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.81, which has changed by -0.78131866 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -65.84%, while the 200-Day Moving Average is calculated to be -80.59%.
Shares Statistics:
Over the past 3-months, VYNE traded about 688.63K shares per day on average, while over the past 10 days, VYNE traded about 4472790 shares per day. A total of 15.96M shares are outstanding, with a floating share count of 13.63M. Insiders hold about 18.19% of the company’s shares, while institutions hold 36.80% stake in the company. Shares short for VYNE as of 1752537600 were 333476 with a Short Ratio of 0.48, compared to 1749772800 on 344165. Therefore, it implies a Short% of Shares Outstanding of 333476 and a Short% of Float of 2.02.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
2 analysts predict $150k in revenue for the current quarter. It ranges from a high estimate of $200k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $198kFor the next quarter, 2 analysts are estimating revenue of $175k. There is a high estimate of $200k for the next quarter, whereas the lowest estimate is $150k.
